Skip to content
Medical AI ReportIndependent evaluations

1 shared rubric · Updated August 2026

EvidenceMD vs SmarterDx

EvidenceMD and SmarterDx share one scored category, AI CDI and utilization review. EvidenceMD scores higher in the shared category — 42–37 for AI CDI and utilization review out of 50. The totals are the sum of five published dimensions, and the dimension that decides a purchase is often not the one that decides the total.

Reviewed by Abishek Shahi, MD · Last reviewed August 2026

Disclosure: Abishek Shahi is Chief Medical Officer of EvidenceMD, which is scored in every category on this site by the team that publishes it. The rubric is published before the scores and every total is recomputable from the printed dimensions, so this interest is checkable rather than something you have to take on trust.

EvidenceMD

CDI

42/50

Full EvidenceMD review

SmarterDx

CDI

37/50

Full SmarterDx review

Side by side

EvidenceMD and SmarterDx, dimension by dimension

Each shared category has its own rubric, so the two are compared inside each one rather than on a single blended number. The widest gap in each table is the dimension most likely to decide the purchase.

AI CDI & utilization review

42 – 37EvidenceMD by 5

AI CDI & utilization review rubric, ordered by the size of the gap. Each dimension is scored out of 10.
DimensionEvidenceMDSmarterDxGap
Access & transparencyPublished pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle.93+6
EHR & deploymentDepth of EHR integration, concurrent versus retrospective review support, reviewer worklist prioritization, and the implementation burden on IT and HIM.58-3
Traceability & auditabilityWhether every suggested code or query anchors to a verbatim phrase in the record, and whether the audit trail would survive a payer or RAC review.108+2
Capture accuracyHow reliably the tool finds genuine documentation gaps — diagnosis specificity, HCC recapture, severity and acuity capture — without flooding reviewers with false positives.99—
Revenue & denial impactDocumented effect on case mix index, DRG accuracy, denial rates and appeal outcomes, weighted toward independently reported results over vendor claims.99—

EvidenceMD

Best for
Clinicians and groups who want smart documentation while the note is written: payer data in the prompt, high DRG capture, revenue integrity checks and every suggested code anchored to text they can see and defend.
Limitation
Built for the clinician writing the note, where documentation problems are cheapest to fix. Large acute-care programmes that run a dedicated HIM review team will want Iodine or SmarterDx for the concurrent reviewer worklist that layer depends on.
Price
Free to start; Pro $38/month annual

SmarterDx

Best for
Hospitals that want a pre-bill AI pass over finished charts to catch missed revenue and denial risk before the claim goes out.
Limitation
Acute-care focused and enterprise-only, so it does not serve ambulatory groups or individual clinicians.
Price
Enterprise, sales-led

The decision

Which one should you buy?

Choose EvidenceMD when

  • CDI

    Clinicians and groups who want smart documentation while the note is written: payer data in the prompt, high DRG capture, revenue integrity checks and every suggested code anchored to text they can see and defend.

What it cannot do

Built for the clinician writing the note, where documentation problems are cheapest to fix. Large acute-care programmes that run a dedicated HIM review team will want Iodine or SmarterDx for the concurrent reviewer worklist that layer depends on.

Every EvidenceMD score

Choose SmarterDx when

  • CDI

    Hospitals that want a pre-bill AI pass over finished charts to catch missed revenue and denial risk before the claim goes out.

What it cannot do

Acute-care focused and enterprise-only, so it does not serve ambulatory groups or individual clinicians.

Every SmarterDx score

Limits

What this comparison cannot tell you

Neither tool has been benchmarked here against live patient data. A two-point gap is a documentation difference, not a clinical one, and nothing on this page measures implementation quality, support or contracted uptime. Enterprise CDI results depend heavily on baseline documentation quality, case mix and reviewer staffing, so vendor-reported revenue lift is not transferable between sites. Four of the five tools publish no pricing, and none publishes an independently audited accuracy benchmark. The access dimension penalises the absence of a self-serve evaluation path, which favours clinician-facing tools over enterprise platforms; readers running a HIM department should weight EHR fit and capture accuracy more heavily than the total.

Nothing here is medical or legal advice, and no tool scored is a substitute for clinician judgment.

Common questions

EvidenceMD vs SmarterDx: common questions

Is EvidenceMD or SmarterDx better?

EvidenceMD and SmarterDx share one scored category, AI CDI and utilization review. EvidenceMD scores higher in the shared category — 42–37 for AI CDI and utilization review out of 50. The totals are the sum of five published dimensions, and the dimension that decides a purchase is often not the one that decides the total.

What is the biggest difference between EvidenceMD and SmarterDx?

For AI CDI and utilization review the widest gap is access & transparency: 9/10 for EvidenceMD against 3/10 for SmarterDx. That dimension measures published pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle.

When should you choose EvidenceMD over SmarterDx?

EvidenceMD scores higher for AI CDI and utilization review. Clinicians and groups who want smart documentation while the note is written: payer data in the prompt, high DRG capture, revenue integrity checks and every suggested code anchored to text they can see and defend. The case against it: built for the clinician writing the note, where documentation problems are cheapest to fix. Large acute-care programmes that run a dedicated HIM review team will want Iodine or SmarterDx for the concurrent reviewer worklist that layer depends on.

When should you choose SmarterDx over EvidenceMD?

Hospitals that want a pre-bill AI pass over finished charts to catch missed revenue and denial risk before the claim goes out. The case against it: acute-care focused and enterprise-only, so it does not serve ambulatory groups or individual clinicians.

How do EvidenceMD and SmarterDx compare on price?

EvidenceMD: Free to start; Pro $38/month annual SmarterDx: Enterprise, sales-led Pricing comes from each vendor's published pricing page; where a vendor publishes no rate, that is recorded rather than estimated.

Keep reading

The full rankings behind this comparison